An experimental pill from Viking Therapeutics (VKTX) reduced liver fat in patients with early signs of fatty liver disease, according to results from a mid-stage clinical trial announced Tuesday.
The promising clinical trial results thrust Viking into the mix of companies racing to develop new treatments for NASH, the commonly used acronym for non-alcoholic steatohepatitis, a chronic disease in which fat accumulates in the liver.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
